Current Report Filing (8-k)
30 April 2022 - 02:13AM
Edgar (US Regulatory)
false 0001762303 0001762303 2022-04-28
2022-04-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28,
2022
AVITA Medical, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-39059 |
|
85-1021707 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
28159 Avenue Stanford, Suite 220,
Valencia, CA 91355 |
|
661.367.9170 |
(Address of principal executive
offices, including Zip Code) |
|
(Registrant’s telephone number,
including area code) |
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per
share |
|
RCEL |
|
The Nasdaq Stock Market
LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the
Securities Exchange Act of 1934. Emerging growth
company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On April 28, 2022, AVITA Medical, Inc. (the “Company”) issued a press release
announcing it will release its first quarter 2022 financial results
on Thursday, May 12, 2022. In conjunction with the release,
the Company plans to host a conference call and webcast that day at
4:30 p.m. Eastern Time to discuss its financial results and recent
highlights. A copy of the Company’s press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
The information under Item 8.01 in this current report on Form
8-K and the related
information in the exhibit attached hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: April 29, 2022 |
|
|
|
|
|
|
|
|
|
|
AVITA MEDICAL, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Donna Shiroma
|
|
|
|
|
Name: |
|
Donna
Shiroma |
|
|
|
|
Title: |
|
General
Counsel |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jun 2022 to Jul 2022
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jul 2021 to Jul 2022